Carna Biosciences, Inc. (4572.T)
JPY 282.0
(0.0%)
JPY 282.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.62 Billion | 1.38 Billion | 2.01 Billion | 1.13 Billion | 3.2 Billion | 754.69 Million |
| Cost of Revenue | 175.29 Million | 171.55 Million | 135.38 Million | 192.14 Million | 207.59 Million | 250.69 Million |
| Gross Profit | 1.45 Billion | 1.21 Billion | 1.88 Billion | 941.19 Million | 2.99 Billion | 503.99 Million |
| Operating Expenses | 2.56 Billion | 2.48 Billion | 2.41 Billion | 1.99 Billion | 2.02 Billion | 1.64 Billion |
| Selling, General and Administrative Expenses | 663.71 Million | 602.76 Million | 571.42 Million | 523.81 Million | 740.07 Million | 507.67 Million |
| Research and Development Expenses | 1.9 Billion | 1.88 Billion | 1.84 Billion | 1.47 Billion | 1.28 Billion | 1.14 Billion |
| Other Expenses | - | 2.48 Billion | 2.41 Billion | 1.99 Billion | 2.02 Billion | -1.18 Million |
| Cost and Expenses | 2.74 Billion | 2.65 Billion | 2.54 Billion | 2.19 Billion | 2.22 Billion | 1.89 Billion |
| Operating Income | -1.11 Billion | -1.26 Billion | -531.13 Million | -1.05 Billion | 977.77 Million | -1.14 Billion |
| Interest Expense | 3.45 Million | 5.31 Million | 3.92 Million | 7.37 Million | 8.16 Million | 10.62 Million |
| Income Tax Expense | 22.04 Million | 26.14 Million | 1.97 Million | 8.54 Million | 84.77 Million | 3.77 Million |
| Earnings before Tax | -1.13 Billion | -1.32 Billion | -532.49 Million | -1.1 Billion | 913.05 Million | -1.2 Billion |
| Net Income | -1.15 Billion | -1.34 Billion | -534.47 Million | -1.11 Billion | 828.28 Million | -1.21 Billion |
| Earnings Per Share Basic | -68.62 | -99.10 | -42.10 | -90.33 | 76.05 | -125.02 |
| Earnings Per Share Diluted | -68.62 | -99.10 | -42.10 | -90.33 | 74.51 | -125.02 |
| Weighted Average Shares Outstanding | 16.8 Million | 13.61 Million | 12.69 Million | 12.29 Million | 10.89 Million | 9.68 Million |
| Weighted Average Shares Outstanding (Diluted) | 16.8 Million | 13.61 Million | 12.69 Million | 12.29 Million | 11.11 Million | 9.68 Million |
| Gross Margin | 0.89 | 0.88 | 0.93 | 0.83 | 0.94 | 0.67 |
| EBIT Margin | -0.67 | -0.90 | -0.25 | -0.93 | 0.30 | -1.51 |
| Profit Margin | -0.71 | -0.97 | -0.26 | -0.98 | 0.26 | -1.60 |
| EBITDA | -1.09 Billion | -1.28 Billion | -509.4 Million | -1.08 Billion | 930.61 Million | -1.18 Billion |
| Earnings Before Tax Margin | -0.69 | -0.92 | -0.26 | -0.93 | 0.30 | -1.52 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 134.77 Million | 180.87 Million | 914.59 Million | 1.62 Billion | 210.72 Million | 273.6 Million |
| Cost of Revenue | 35.96 Million | 46.67 Million | 51.64 Million | 175.29 Million | 40.96 Million | 34.04 Million |
| Gross Profit | 98.81 Million | 134.2 Million | 862.94 Million | 1.45 Billion | 169.76 Million | 239.55 Million |
| Operating Expenses | 777.57 Million | 550.43 Million | 778.16 Million | 2.56 Billion | 507.82 Million | 597.45 Million |
| Selling, General and Administrative Expenses | 162.54 Million | 173.02 Million | 778.16 Million | - | 144.11 Million | 173.11 Million |
| Research and Development Expenses | 615.02 Million | 377.41 Million | 580.55 Million | - | 363.71 Million | 424.34 Million |
| Other Expenses | 2.27 Million | -77 Thousand | -67 Thousand | -517 Thousand | -77 Thousand | -157 Thousand |
| Cost and Expenses | 813.53 Million | 597.1 Million | 829.81 Million | 2.74 Billion | 548.78 Million | 631.5 Million |
| Operating Income | -678.76 Million | -416.23 Million | 84.77 Million | -1.11 Billion | -338.05 Million | -357.9 Million |
| Interest Expense | 800 Thousand | 926 Thousand | 1.06 Million | 3.45 Million | 692 Thousand | 799 Thousand |
| Income Tax Expense | 950 Thousand | 1.78 Million | -397 Thousand | 22.04 Million | 6.22 Million | 10.84 Million |
| Earnings before Tax | -694.27 Million | -397.1 Million | 77.05 Million | -1.13 Billion | -338.5 Million | -355.55 Million |
| Net Income | -695.22 Million | -398.89 Million | 77.44 Million | -1.15 Billion | -344.73 Million | -366.39 Million |
| Earnings Per Share Basic | -39.98 | -23.27 | 4.52 | - | -20.13 | -21.46 |
| Earnings Per Share Diluted | -39.98 | -23.27 | 4.52 | - | -20.13 | -21.46 |
| Weighted Average Shares Outstanding | 17.38 Million | 17.14 Million | 17.14 Million | 16.8 Million | 17.12 Million | 17.07 Million |
| Weighted Average Shares Outstanding (Diluted) | 17.38 Million | 17.14 Million | 17.14 Million | 16.8 Million | 17.12 Million | 17.07 Million |
| Gross Margin | 0.73 | 0.74 | 0.94 | 0.89 | 0.81 | 0.88 |
| EBIT Margin | -4.98 | -2.26 | 0.10 | - | -1.59 | -1.29 |
| Profit Margin | -5.16 | -2.21 | 0.08 | -0.71 | -1.64 | -1.34 |
| EBITDA | -670.86 Million | -408.65 Million | 94.84 Million | - | -334.23 Million | -354.23 Million |
| Earnings Before Tax Margin | -5.04 | -2.30 | 0.09 | -0.69 | -1.60 | -1.31 |
BIOV
DNM
0105
0817
UCID
DPAINT